01—Abstract
Summary
Summary of the 8-K filed April 7, 2017. Cited figures are marked; the original filing is the authoritative source.
Ecolab Inc. (ECL) filed an 8-K on April 7, 2017, primarily to provide investors with supplemental unaudited financial information.
This filing includes revised segment net sales and operating income data for the years ended December 31, 2016, and December 31, 2015. The adjustments reflect international operations at fixed currency exchange rates established at the beginning of 2017, and the creation of a new 'Life Sciences' operating segment. These changes are intended to better align with the company's strategic growth initiatives, particularly in pharmaceutical and personal care manufacturing.
02—Key points
Key Highlights
- Supplemental financial data provided for 2016 and 2015 segment net sales and operating income.
- Adjustments made to reflect international operations at fixed currency exchange rates (2017 rates).
- Introduction of a new 'Life Sciences' operating segment effective Q1 2017.
- The new segment is designed to support growth in pharmaceutical and personal care manufacturing operations.
- Immaterial changes to customer allocations and cost distributions between segments are also reflected.
- This information is supplemental and does not replace previously filed financial statements (10-Q, 10-K).
- Information furnished is not deemed 'filed' under Section 18 of the Exchange Act, limiting liability.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The primary purpose of this 8-K filing is to provide investors with supplemental, unaudited financial information regarding Ecolab's operating segments. This includes adjusted net sales and operating income for 2015 and 2016, reflecting a new way of presenting international results and the creation of a new business segment.
What are the key changes reflected in the supplemental financial data?
The key changes involve presenting international operations at fixed currency exchange rates (set at the beginning of 2017) and establishing a new 'Life Sciences' operating segment. There are also minor adjustments for customer and cost reallocations between segments.
Why is Ecolab creating a new 'Life Sciences' segment?
The 'Life Sciences' operating segment is being established to better align with Ecolab's strategy for growth in its pharmaceutical and personal care manufacturing operations.
Does this supplemental information replace Ecolab's official financial statements?
No, this information is supplemental and is not intended to replace the financial data reported in Ecolab's previously filed Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
04—Continue